trending Market Intelligence /marketintelligence/en/news-insights/trending/gZMo7cT1EY-k-J8XEsG1Lw2 content esgSubNav
In This List

US appeals court dismisses Amgen's demand to ban Sanofi, Regeneron drug

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


US appeals court dismisses Amgen's demand to ban Sanofi, Regeneron drug

The U.S. Court of Appeals for the Federal Circuit dismissed a permanent injunction on the sale of Sanofi and Regeneron Pharmaceuticals Inc.'s cholesterol-lowering drug Praluent, Reuters reported Oct. 5.

Amgen Inc., which markets a rival cholesterol drug, Repatha, had brought a lawsuit claiming that Praluent infringed on two of its patents related to a protein known as proprotein convertase subtilisin/kexin 9, or PCSK9.

U.S. District Judge Sue Robinson in Delaware granted Amgen's motion in January, banning Sanofi and Regeneron from selling and making Praluent in the U.S.

However, the U.S. Court of Appeals for the Federal Circuit in February allowed Praluent sales to continue while the firms sorted out the patent infringement suit.